A claim you hear on longevity podcasts

Does EPA omega-3 work as well as antidepressants?

The claim checked: At least 1 to 3 grams a day of EPA can lift mood at least as well as some major antidepressants Hear it at 16:31

What do the studies say?

Leaning for

Of ten studies, three found EPA or omega-3 eased depression and one pooled analysis found no clear effect. Six gave partial support: small, mixed or subgroup-only effects, one with no added benefit above 1 g a day.

Computed from 10 studies that test this point, each judged by two readers, in full. 4 more studies are waiting for a full read and do not count yet.

What was said on the podcast?

“And indeed, there's a wealth of literature now pointing to the fact that ingesting at least one, or two, or even three grams per day of EPA form of essential fatty acid can have effects, positive effects, on mood and wellbeing that are at least on par with some of the major antidepressant treatments out there,”
Andrew Huberman, Huberman Lab · Nutrients For Brain Health & Performance | Huberman Lab Podcast #42 · 16:31 on YouTube
Comes up in 6 episodes of the show.
Point 1 of 2 Leaning for

At least 1 g/day of EPA improves depression and mood

Agree 3

pooled analysis · 2016 · landmark

“In conclusion, the present meta-analysis observed a beneficial overall effect of omega-3 PUFA supplementation in patients with MDD according to diagnostic criteria, which seemed larger in studies that supplemented higher doses of EPA and included patients taking antidepressants.”

Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry
Who: Adults with DSM-diagnosed major depressive disorder confirmed by structured clinical interview; perinatal/perimenopausal and secondary MDD excluded
PMID 26978738

pooled analysis · 2011

“Supplements containing EPA ≥ 60%, in dose range 200 to 2200 mg EPA in excess of DHA, were effective against primary depression.”

Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry
Who: 15 double-blind placebo-controlled trials of omega-3 PUFA in patients with a depressive episode as primary complaint (MDD, bipolar depression, perinatal, comorbid Parkinson's or CHD; one pediatric trial)
PMID 21939614

controlled trial · 2006

“Treatment of bipolar depression with adjunctive ethyl-EPA resulted in improved clinical outcomes compared with placebo in terms of reduction in HRSD and CGI scores.”

Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry
Who: 75 outpatients aged 18-70 with bipolar I or II disorder in a depressive phase (HRSD-17 >=10), single centre in London
PMID 16388069

Partly agree 6

pooled analysis · 2014 · landmark

“Among the tot studies included [52] , [66] , [67] , [88] , [101] , [102] , the overall analysis showed a nearly null effect of this supplement on depressive symptoms in healthy subjects (standardized mean difference – fixed and random effects-model: 0.00 SD, 95% CI: −0.13, 0.13).”

Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One
Who: Placebo-controlled RCTs of omega-3 in people with depressive symptoms (MDD, non-MDD depression, bipolar, perinatal, comorbid disease) and healthy subjects
PMID 24805797

pooled analysis · 2019 · landmark

“We found no apparent benefit of a higher dosage (>1 g/d) of either EPA-pure or EPA-major treatment for depression.”

Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl Psychiatry
Who: adults with depression (mostly DSM-diagnosed MDD) in double-blind RCTs, excluding bipolar disorder, Parkinson's and pregnancy
PMID 31383846

controlled trial · 2016 · landmark

“While overall treatment group differences for the entire sample were negligible (ES=−0.13 to +0.04), subjects with one or more “high” biomarker of inflammation improved more on EPA than placebo (ES=−0.39) or DHA (ES=−0.60) and less on DHA than placebo (ES=+0.21).”

Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry
Who: 155 adults aged 18-80 with DSM-IV major depressive disorder (HAM-D-17 >=15) not on psychotropic medication
PMID 25802980

Show 3 more Show fewer

controlled trial · 2012

“Following the removal of this outlier, there was a significant improvement in depression (GDS) scores in the EPA (P = 0·04) and DHA (P = 0·01) groups compared with the LA group (Fig. 2; Table 3).”

Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr
Who: 50 Australian adults aged >65 years with mild cognitive impairment (36% with GDS scores indicating possible depression)
PMID 21929835

controlled trial · 2014

“Compared with placebo, the incident rates of IFN-α-induced depression were significantly lower in EPA-treated but not in DHA-treated patients (10% and 28%, respectively, versus 30% for placebo, p = .037).”

Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol Psychiatry
Who: Chronic hepatitis C patients in Taiwan without current major depression, about to start interferon-alpha therapy (mean age ~53)
PMID 24602409

pooled analysis · 2006

“The evidence available provides little support for the use of n–3 PUFAs to improve depressed mood.”

Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr
Who: participants in 18 RCTs of n-3 PUFAs with depressed mood measured (unipolar and bipolar depression, schizophrenia, chronic fatigue, postpartum depression, angina, healthy volunteers; one trial in children)
PMID 17158410

Disagree 1

pooled analysis · 2012

“Meta-analysis showed no significant effect of omega-3 fatty acids for the treatment of depression (SMD=0.11, 95% Confidence Interval (CI): -0.04, 0.26, p=0.14).”

Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry
Who: adults with major depressive disorder (including peripartum MDD and MDD with medical comorbidity) in randomized double-blind placebo-controlled trials; bipolar, schizophrenia and other primary disorders excluded
PMID 21931319

Point 2 of 2 Leaning for

The effect is on par with some major antidepressants

Three pooled analyses and reviews found effects comparable to antidepressants, and one trial found lower response rates. Three gave partial support: one trial found a moderate effect with lower response rates, and two reviews found too little head-to-head data to be sure.

Computed from 7 studies that test this point, each judged by two readers, in full. 10 more studies are waiting for a full read and do not count yet.

Agree 3

pooled analysis · 2016 · landmark

“Overall, with an standardized mean difference of 0.398 present meta-analysis shows a beneficial effect of omega-3 PUFAs that is comparable to effects reported in meta-analyses of antidepressants.”

Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry
Who: Adults with DSM-diagnosed major depressive disorder confirmed by structured clinical interview
PMID 26978738

pooled analysis · 2016

“The effect size for EPA-predominant formulations in clinical depression (G = 0.61) is comparable with that of conventional antidepressants but high or statistically significant effect sizes do not in themselves demonstrate a genuine effect.”

Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry
Who: Children and adults in double-blind placebo-controlled trials of omega-3 for depressive symptoms in affective disorders, with and without diagnosed depression
PMID 27103682

systematic review · 2025

“Among nutraceutical monotherapies, EPA + DHA, SAMe, curcumin, and saffron exhibited higher efficacy than ADT alone.”

Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis. Psychol Med
Who: adults diagnosed with depressive disorder in RCTs of nutraceuticals
PMID 40314175

Partly agree 3

pooled analysis · 2015

“The one study that directly compares n-3PUFAs and antidepressants in our review finds comparable benefit.”

Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev
Who: Adults with a diagnosis of major depressive disorder in RCTs of n-3PUFAs vs placebo or vs antidepressant
PMID 26537796

controlled trial · 2009

“Although our response rates were lower than those generally reported for synthetic antidepressants, the effect size for EPA was within the moderate range for completers and for the ITT sample.”

A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry
Who: adults 18-80 with DSM-IV major depressive disorder (HAM-D-17 >=18), not on antidepressants, excluding those who failed an adequate antidepressant trial
PMID 19709502

systematic review · 2021

“Confidence intervals are however very wide in all analyses, and do not rule out important beneficial or detrimental effects of n‐3PUFAs compared to antidepressants.”

Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev
Who: adults with major depressive disorder in 35 RCTs (34 vs placebo, 1 vs antidepressant)
PMID 34817851

Disagree 1

controlled trial · 2015

“Response rates for the n-3 preparations were somewhat lower than the known efficacy rates of established antidepressants.”

A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry
Who: Unmedicated adult outpatients with DSM-IV major depressive disorder, HDRS-17 >=15, at MGH and Cedars-Sinai (mean age 44.7, 53% female)
PMID 25272149

What else was said but not tested?

  • Without comparable side effects
  • Adding 1-3 g EPA lets people on antidepressants use a lower dose
  • More (2-3 g) is fine or better ('or even three grams')

More on supplements and drugs

All checked claims · How we check a claim

How Precis checks a claim · Report an error

The Precis Weekly

Get each new check by email.

One email a week with the claims and episodes we checked, what the studies found and the minute each claim was said.

Free. Unsubscribe anytime.